22 research outputs found
Transglutaminase inhibition: possible therapeutic mechanisms to protect cells from death in neurological disorders.
Neuronutraceuticals Modulate Lipopolysaccharide- or Amyloid-β 1-42 Peptide-Induced Transglutaminase 2 Overexpression as a Marker of Neuroinflammation in Mouse Microglial Cells
Background: Tissue type 2 Transglutaminase (TG2, E.C. 2.3.2,13) is reported to be involved in phagocytosis of apoptotic cells in mouse microglial BV2 cells and peripheral macrophages. In this study, by using Lipopolysaccharide (LPS)- or Amyloid-beta 1-42 (Abeta 1-42) peptide-stimulated mi-croglial cell line BV2 and mouse primary microglial cells, we examined the effects of different neuronutraceutical compounds, such as Curcumin (Cu) and N-Palmitoylethanolamine (PEA), known for their anti-inflammatory activity, on TG2 and several inflammatory or neuroprotective biomarkers expressions. Methods: Mouse BV2 cells were treated with LPS or Abeta1-42 in presence of Curcumin or PEA, in order to evaluate the expression of TG2 and other inflammatory or neuro-protective markers by RealTime PCR and Western Blot analyses. Results: Curcumin and PEA were capable to reduce TG2 expression in mouse microglial cells during co-treatment with LPS or Abeta 1-42. Conclusions: The results show the role of TG2 as an important marker of neuroinflamma-tion and suggest a possible use of Curcumin and PEA, in order to reduce LPS- or Abeta1-42-induced TG2 overexpression in mouse microglial cells
Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries
Abstract
Background
Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres.
Methods
This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries.
Results
In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia.
Conclusion
This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries
Neuronutraceuticals Modulate Lipopolysaccharide- or Amyloid-β 1-42 Peptide-Induced Transglutaminase 2 Overexpression as a Marker of Neuroinflammation in Mouse Microglial Cells
Background: Tissue type 2 transglutaminase (TG2, E.C. 2.3.2,13) is reported to be involved in the phagocytosis of apoptotic cells in mouse microglial BV2 cells and peripheral macrophages. In this study, by using lipopolysaccharide (LPS)- or amyloid-β 1-42 (Aβ 1-42) peptide-stimulated microglial cell line BV2 and mouse primary microglial cells, we examined the effects of different neuronutraceutical compounds, such as curcumin (Cu) and N-Palmitoylethanolamine (PEA), known for their anti-inflammatory activity, on TG2 and several inflammatory or neuroprotective biomarker expressions. Methods: Mouse BV2 cells were treated with LPS or Aβ1-42 in the presence of curcumin or PEA, in order to evaluate the expression of TG2 and other inflammatory or neuroprotective markers using Real Time-PCR and Western blot analyses. Results: Curcumin and PEA were capable of reducing TG2 expression in mouse microglial cells during co-treatment with LPS or Aβ 1-42. Conclusions: The results show the role of TG2 as an important marker of neuroinflammation and suggest a possible use of curcumin and PEA in order to reduce LPS- or Aβ1-42-induced TG2 overexpression in mouse microglial cells
Possible roles of transglutaminases in molecular mechanisms responsible for human neurodegenerative diseases.
Transglutaminases are a family of Ca2+-dependent enzymes which catalyze posttranslational
modifications of proteins. The main activity of these enzymes is the cross-linking of
glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate.
In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or
polyamines (to form mono- or bi-substituted/crosslinked adducts) or –OH groups (to form ester
linkages). In absence of co-substrates, the nucleophile may be water, resulting in the net deamidation
of the glutaminyl residue. Transglutaminase activity has been suggested to be involved in molecular
mechanisms responsible for both physiological or pathological processes. In particular,
transglutaminase activity has been shown to be responsible for human autoimmune diseases, Celiac
Disease is just one of them. Interestingly, neurodegenerative diseases, such as Alzheimer’s Disease,
Parkinson’s Disease, supranuclear palsy, Huntington’s Disease and other polyglutamine diseases, are
characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked
proteins in affected brains. This review describes the possible molecular mechanisms by which these
enzymes could be responsible for such diseases and the possible use of transglutaminase inhibitors
for patients with diseases characterized by aberrant transglutaminase activity
PHYSIOPATHOLOGICAL ROLES OF THE HUMAN TRANSGLUTAMINASE 2, THE “TISSUE” TRANSGLUTAMINASE (TG2), AND ITS POSSIBLE INVOLVEMENT IN NEURODEGENERATIVE DISEASES
Transglutaminase 2 (TG2, “tissue” TG) belongs to the family of the Transglutaminase (TG) enzymes, which catalyse post-translational modifications of proteins, such as the cross linking of a glutaminyl residue of a protein/peptide substrate to a lysyl residue of a protein/peptide co-substrate with the formation of an N-gamma-(epsilon-L-glutamyl)-L-lysine [GGEL] cross link (isopeptidic bond) and the concomitant release of ammonia
Transglutaminase Activity as a Possible Molecular Mechanism in the Etiopathogenesis of Neurodegenerative Diseases
Transglutaminase inhibition: possible therapeutic mechanisms to protect cells from death in neurological disorders
Transglutaminases are a family of Ca2+-dependent enzymes which catalyze post-translational modifications of proteins. The main activity of these enzymes is the cross-linking of glutaminyl residues of a protein/peptide substrate to lysyl residues of a protein/peptide co-substrate. In addition to lysyl residues, other second nucleophilic co-substrates may include monoamines or polyamines (to form mono-or bi-substituted/crosslinked adducts) or -OH groups (to form ester linkages). In absence of co-substrates, the nucleophile may be water, resulting in the net deamidation of the glutaminyl residue. Transglutaminase activity has been suggested to be involved in molecular mechanisms responsible for both physiological and pathological processes. In particular, transglutaminase activity has been shown to be responsible for human autoimmune diseases, and Celiac Disease is just one of them. Interestingly, neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, supranuclear palsy, Huntington’s disease and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. Here we describe the possible molecular mechanisms by which these enzymes could be responsible for such diseases and the possible use of transglutaminase inhibitors for patients with diseases characterized by aberrant transglutaminase activity
Transglutaminase Inhibition as a Possible Therapeutic Mechanism to Protect Cells from Death in Neurological Disorders
Curcumin (Diferulolylmethane) Reduces Transglutaminase 2 Overexpression Induced by Retinoic Acid in Human Nervous Cell Lines
Abstract
Objectives: Curcumin, a naturally occurring compound derived from turmeric (Curcuma longa) has long been suggested to have strong therapeutic or preventive potential against human diseases because of its antioxidative, anticancerous, and anti-inflammatory effects. Curcumin is known to exert anti-inflammatory effects by interrupting NF-κB signaling at multiple levels. Many observations indicate that curcumin shows its valuable potential by inhibiting the activity of I-κB kinase. Transglutaminase 2 (TG2) expression is increased in inflammatory diseases. Data in the literature suggest that this enzyme activates the proinflammatory transcriptional factor NF-κB by inducing the polymerization of its inhibitory subunit I-κBα, which in turn results in the dissociation of NF- κB and its translocation to the nucleus, where it is capable of upregulating host inflammatory genes. Interestingly, NF-κB regulatory response elements are also present in the TG2 promoter, suggesting a possible role for this pathway in the mechanism responsible for chronic inflammation. On the basis of these literature data, our objective was to analyze the effects of curcumin on TG2 expression in human nervous cell lines. Methods: Human nervous cell lines were treated with curcumin alone or in association with retinoic acid in order to induce TG2 overexpression. TG2 levels were analyzed by Western blot and real-time PCR analyses. Results: Curcumin was able to downregulate the expression of TG2 in human nervous cell lines, which was also the case after treatment with retinoic acid. Conclusions: These results suggest a possible use of curcumin in reducing TG2 overexpression
in human nervous cells